Roche

News

Graphical representation of Brainshuttle antibody at the blood-brain barrier

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.

News

Multiple studies of Sarepta's DMD therapy halted after death

Three studies of Sarepta's Elevidys Duchenne gene therapy have been placed on hold as the death of a 16-year-old boy is investigated.

News

Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at WashU Medicine

Gantenerumab 'shows sign of preventing Alzheimer's dementia'

A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.

News

Roche taps Oxford BioTherapeutics for cancer drug discovery

Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.

News

Roche builds in obesity with $5.3bn Zealand licensing deal

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.

News

FDA starts review of Roche's Gazyva in lupus nephritis

FDA starts a review of Roche's Gazyva as a treatment for lupus nephritis, an indication that analysts think could unlock renewed sales growth.

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Multiple studies of Sarepta's DMD therapy halted after death

Gantenerumab 'shows sign of preventing Alzheimer's dementia'

Roche taps Oxford BioTherapeutics for cancer drug discovery

Roche builds in obesity with $5.3bn Zealand licensing deal

FDA starts review of Roche's Gazyva in lupus nephritis

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks